Tenax Therapeutics Inc (TENX) - Kewajiban jangka dawa marang modal

This chart of the long-term debt-to-equity ratio reflects expectations for the final trials of the primary cardiovascular drug, with the current parameter equal to 0.00. The stability of Tenax Therapeutics (TENX) is based on a diversified development portfolio aimed at combating pulmonary hypertension. High confidence from specialized physicians confirms its status as a cardiology expert creating innovative solutions to improve blood flow for critically ill patients.

For Tenax Therapeutics (TENX), the long-term debt-to-equity ratio reflects the balance between borrowed financing and equity. This metric measures the proportion of liabilities with a maturity exceeding one year, determining financial stability and the cost of resources. By analyzing the ratio of long-term loans to equity, an investor can discern the degree of dependence on external borrowing. Amid geopolitical risks for the biopharmaceutical sector, low leverage is critical for protecting clinical trials. Optimizing this indicator minimizes default risk during global supply chain disruptions.